Examining the role of neuroinflammation in major depression

Psychiatry Research

Volumn 229, Issue 1-2, 2015, Pages 27-36

  Furtado, Melissa ^a   Katzman, Martin A ^a,b,c,d,e  

^a START Clinic for Mood and Anxiety Disorders   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^d LAKEHEAD UNIVERSITY   (Canada)

^e Adler Graduate Professional School   (Canada)

Author keywords

Hypothalamic pituitary adrenal axis; Inflammation; Interleukin; Major depression; Tumor necrosis factor

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; ESCITALOPRAM; FLUVOXAMINE; INTERLEUKIN 6; MILNACIPRAN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; AUTACOID;

B LYMPHOCYTE; BRAIN REGION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DORSOLATERAL PREFRONTAL CORTEX; DRUG EFFICACY; DRUG RESPONSE; HELPER CELL; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MAJOR DEPRESSION; NERVOUS SYSTEM INFLAMMATION; PAIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SOMATOSENSORY CORTEX; SYSTEMATIC REVIEW; T LYMPHOCYTE; THALAMUS; TREATMENT DURATION; BLOOD; DEPRESSIVE DISORDER, MAJOR; EARLY DIAGNOSIS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; STATISTICS;

C-REACTIVE PROTEIN; DEPRESSIVE DISORDER, MAJOR; EARLY DIAGNOSIS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION MEDIATORS; INTERLEUKIN-6; PITUITARY-ADRENAL SYSTEM; STATISTICS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939430077     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.06.009     Document Type: Review

References (79)

1. Adzic M., Djordjevic J., Djordjevic A., Niciforovic A., Demonacos C., Radojcic M., Krstic-Demonacos M. Acute or chronic stress induce cell compartment-specific phosphorylation of glucocorticoid receptor and alter its transcriptional activity in Wistar rat brain. Journal of Endocrinology 2009, 202(1):87-97.
2. Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, American Psychiatric Publishing, Washington. fourth ed., text rev.
3. Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Association, American Psychiatric Publishing, Arlington. fifth ed.
4. Bai Y.M., Chiou W.F., Su T.P., Li C.T., Chen M.H. Pro-inflammatory cytokine associated with somatic and pain symptoms in depression. Journal of Affective Disorders 2014, 155:28-34.
5. Benton T., Staab J., Evans D.L. Medical co-morbidity in depressive disorders. Annals of Clinical Psychiatry 2007, 19(4):289-303.
6. Berger A. Th1 and Th2 responses: what are they?. BMJ 2000, 321(7258):424.
7. Bressi C., Taylor G., Parker J., Bressi S., Brambilla V., Aguglia E., et al. Cross validation of the factor structure of the 20-item Toronto Alexithymia Scale: an Italian multicenter study. Journal of Psychosomatic Research 1996, 41(6):551-559.
8. Cizza G., Eskandari F., Coyle M., Krishnamurthy P., Wright E.C., Mistry S., Csako G. Plasma CRP levels in premenopausal women with major depression: a 12-month controlled study. Hormone and Metabolic Research 2009, 41(8):641-648. P.O.W.E.R. (Premenopausal, Osteoporosis Women, Alendronate, Depression) Study Group.
9. Cowen P.J. Cortisol, serotonin and depression: all stressed out?. The British Journal of Psychiatry 2002, 180:99-100.
10. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., Lowe G.D., Pepys M.B., Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. The New England Journal of Medicine 2004, 350(14):1387-1397.
11. Dannehl K., Rief W., Schwarz M.J., Hennings A., Riemer S., Selberdinger V., Stapf T., Euteneuer F. The predictive value of somatic and cognitive depressive symptoms for cytokine changes in patients with major depression. Journal of Neuropsychiatric Disease and Treatment 2014, 10:1191-1197.
12. De Berardis D., Serroni N., Campanella D., Carano A., Gambi F., Valchera A., Conti C., Sepede G., Scali M., Fulcheri M., Salerno R.M., Ferro F.M. Alexithymia and its relationships with c-reactive protein and serum lipid levels among drug naïve adult outpatients with major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008, 32:1982-1986.
13. Dean B., Tawadros N., Scarr E., Gibbons A.S. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. Journal of Affective Disorders 2010, 120(1-3):245-248.
14. Diniz B.S., Teixeira A.L., Talib L.L., Mendonça V.A., Gattaz W.F., Forlenza O.V. Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. Journal of Psychiatric Research 2010, 44(14):917-920.
15. Euteneuer F., Schwarz M.J., Hennings A., Riemer S., Stapf T., Selberdinger V., Rief W. Depression, cytokines and experimental pain: evidence for sex-related association patterns. Journal of Affective Disorders 2011, 131(1-3):143-149.
16. Felger J.C., Lotrich F.E. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246:199-229.
17. Ferrari A.J., Charlson F.J., Norman R.E., Patten S.B., Freedman G., Murray C.J., Vos T., Whiteford H.A. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Medicine 2013, 10(11):e1001547.
18. Fitzgerald P., O'Brien S.M., Scully P., Rijkers K., Scott L.V., Dinan T.G. Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychological Medicine 2006, 36(1):37-43.
19. Gartlehner G., Hansen R.A., Morgan L.C., Thaler K., Lux L., Van Noord M., Mager U., Thieda P., Gaynes B.N., Wilkins T., Strobelberger M., Lloyd S., Reichenpfader U., Lohr K.N. Comparative benefits and harms of second-generation antidepressant for treating major depressive disorder: an updated meta-analysis. Annals of Internal Medicine 2011, 155(11):772-785.
20. Grassi-Oliveira R., Brietzke E., Pezzi J.C., Lopes R.P., Teixeira A.L., Bauer M.E. Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder. Psychiatry and Clinical Neurosciences 2009, 63(2):202-208.
21. Hess A., Axmann R., Rech J., Finzel S., Heindl C., Kreitz S., Sergeeva M., Saake M., Garcia M., Kollias G., Straub R.H., Sporns O., Doerfler A., Brune K., Schett G. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proceedings of the National Academy of Sciences 2011, 108(8):3731-3736.
22. Hinkelmann K., Moritz S., Botzenhardt J., Muhtz C., Widermann K., Kellner M., Otte C. Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study. Psychoneuroendocrinology 2012, 37(5):685-692.
23. Honkalampi K., Hintikka J., Saarinen P., Lehtonen J., Viinamaki H. Is alexithymia a permanent feature in depressed outpatients? Results from a 6-month follow-up study. Psychotherapy and Psychosomatics 2000, 69:303-308.
24. Iannacone M., Sitia G., Isogawa M., Marchese P., Castro M.G., Lowenstein P.R., Chisari F.V., Ruggeri Z.M., Guidotti L.G. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nature Medicine 2005, 11(11):1167-1169.
25. Janelidze S., Mattei D., Westrin Å., Träskman-Bendz L., Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain, Behavior, and Immunity 2011, 25(2):335-339.
26. Jeanmonod P., von Kanel R., Maly F.E., Fischer J.E. Elevated plasma C-reactive protein in chronically distressed subjects who carry the a allele of the TNF-alpha-308G/A polymorphism. Psychosomatic Medicine 2004, 66:501-506.
27. Karlović D., Serretti A., Vrkić N., Martinac M., Marčinko D. Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Research 2012, 198(1):74-80.
28. Kessler R.C., Petukhova M., Sampson N.A., Zaslavsky A.M., Wittchen H.U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. International Journal of Methods in Psychiatric Research 2012, 21(3):169-184.
29. Koenig W., Sund M., Fröhlich M., Fischer H.G., Löwel H., Döring A., Hutchinson W.L., Pepys M.B. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99(2):237-242.
30. Köhler O., Benros M.E., Nordentoft M., Farkouh M.E., Iyengar R.L., Mors O., Krogh J. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014, 71(12):1381-1391.
31. Krogh J., Benros M.E., Jørgensen M.B., Vesterager L., Elfving B., Nordentoft M. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain, Behavior, and Immunity 2014, 35:70-76.
32. Lam R.W. Sleep disturbances and depression: a challenge for antidepressants. International Clinical Psychopharmacology 2006, 21:S25-S29.
33. Lamers F., van Oppen P., Comijs H.C., Smit J.H., Spinhoven P., van Balkom A.J., Nolen W.A., Zitman F.G., Beekman A.T., Penninx B.W. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). Journal of Clinical Psychiatry 2011, 72(3):341-348.
34. Lesch K.P. Gene-environment interaction and the genetics of depression. Journal of Psychiatry & Neuroscience 2004, 29(3):174-184.
35. Marazziti D., Castrogiovanni P., Rossi A., Rosa C., Ghione S., Di Muro A., Panattoni E., Cassano G.B. Pain threshold is reduced in depression. International Journal of Neuropsychopharmacology 1998, 1(1):45-48.
36. Markopoulou K., Papadopoulos A., Juruena M.F., Poon L., Pariante C.M., Cleare A.J. The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinology 2009, 34:19-26.
37. McKay M.S., Zakzanis K.K. The impact of treatment on HPA axis activity in unipolar major depression. Journal of Psychiatric Research 2010, 44(3):183-192.
38. McQuade R., Young A.H. Future therapeutic targets in mood disorders: the glucocorticoid receptor. The British Journal of Psychiatry 2000, 177:390-395.
39. Milstein O., Hagin D., Lask A., Reich-Zeliger S., Shezen E., Ophir E., Eidelstein Y., Afik R., Antebi Y.E., Dustin M.L., Reisner Y. CTLs respond with activation and granule secretion when serving as targets for T-cell recognition. Blood 2011, 117(3):1042-1052.
40. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology 1989, 7:145-173.
41. Nemeroff C.B., Vale W.W. The neurobiology of depression: inroads to treatment and new drug discovery. Journal of Clinical Psychiatry 2005, 66(Suppl. 7):5-13.
42. Nemeroff C.B., Goldschmidt-Clermont P.J. Heartache and heartbreak-the link between depression and cardiovascular disease. Nature Reviews Cardiology 2012, 9(9):526-539.
43. Nordestgaard B.G. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. Current Opinion in Lipidology 2009, 20(5):393-401.
44. Nutt D., Wilson S., Paterson L. Sleep disorders as core symptoms of depression. Dialogues in Clinical Neurosciences 2008, 10:329-336.
45. O'Brien S.M., Scully P., Fitzgerald P., Scott L.V., Dinan T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. Journal of Psychiatric Research 2007, 41:326-331.
46. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends in Neurosciences 2008, 31(9):464-468.
47. Park S., Joo Y.H., McIntyre R.S., Kim B. Metabolic syndrome and elevated C-reactive protein levels in elderly patients with newly diagnosed depression. Psychosomatics 2014, 55:640-649.
48. Pasco J.A., Nicholson G.C., Williams L.J., Jacka F.N., Henry M.J., Hotowicz M.A., Schneider H.G., Leonard B.E., Berk M. Association of high-sensitivity C-reactive protein with de novo major depression. The British Journal of Psychiatry 2010, 197(5):372-377.
49. Pavón L., Sandoval-López G., Eugenia Hernández M., Loría F., Estrada I., Pérez M., Moreno J., Avila U., Leff P., Antón B., Heinze G. Th2 cytokine response in Major Depressive Disorder patients before treatment. Journal of Neuroimmunology 2006, 172(1-2):156-165.
50. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. Journal of Clinical Investigation 2003, 111(12):1805-1812.
51. Perahia D.G., Quail D., Desaiah D., Montejo A.L., Schatzberg A.F. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. Journal of Psychiatric Research 2009, 43(5):512-518.
52. Powell T.R., Schalkwyk L.C., Heffernan A.L., Breen G., Lawrence T., Price T., Farmer A.E., Aitchison K.J., Craig I.W., Danese A., Lewis C., McGuffin P., Uher R., Tansey K.E., D'Souza U.M. Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. European Neuropsychopharmacology 2013, 23(9):1105-1114.
53. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70(1):31-41.
54. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107(3):363-369.
55. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. The New England Journal of Medicine 2000, 342(12):836-843.
56. Romagnani S. T-cell subsets (Th1 versus Th2). Annals of Allergy, Asthma & Immunology 2000, 85(1):9-18.
57. Rudolf S., Greggersen W., Kahl K.G., Hüppe M., Schweiger U. Elevated IL-6 levels in patients with atypical depression but not in patients with typical depression. Psychiatry Research 2014, 217(1-2):34-38.
58. Saarijarvi S., Salminen J.K., Toikka T. Alexithymia and depression: a 1-year follow-up study in outpatients with major depression. Journal of Psychosomatic Research 2001, 51:729-733.
59. Saarijarvi S., Salminen J.K., Toikka T. Temporal stability of alexithymia over a five-year period in outpatients with major depression. Psychotherapy and Psychosomatics 2006, 75:107-112.
60. Schuhmacher A., Lennertz L., Wagner M., Höfels S., Pfeiffer U., Guttenthaler V., Maier W., Zobel A., Mössner R. A variant of the neuronal amino acid transporter SLC6A15 is associated with ACTH and cortisol responses and cognitive performance in unipolar depression. International Journal of Neuropsychopharmacology 2013, 16(1):83-90.
61. Sharma R.P., Tun N., Grayson D.R. Depolarization induces downregulation of DNMT1 and DNMT3a in primary cortical cultures. Epigenetics 2008, 3(2):74-80.
62. Simpson R.J., Hammacher A., Smith D.K., Matthews J.M., Ward L.D. Interleukin-6: structure-function relationships. Protein Science 1997, 6(5):929-955.
63. Somerville L.H., Heatherton T.F., Kelley W.M. Anterior cingulate cortex responds differentially to expectancy violation and social rejection. Nature Neuroscience 2006, 9(8):1007-1008.
64. Sturgeon J.A., Darnall B.D., Zwickey H.L., Wood L.J., Hanes D.A., Zava D.T., Mackey S.C. Proinflammatory cytokines and DHEA-S in women with fibromyalgia: impact of psychological distress and menopausal status. Journal of Pain Research 2014, 7:707-716.
65. Taylor G.K., Bagby R.M., Parker J.D.A. Disorders of affect regulation: Alexithymia in medical and psychiatric illness 1997, Cambridge University Press, Cambridge.
66. Thomas A.J., Ferrier I.N., Kalaria R.N., Woodward S.A., Ballard C., Oakley A., Perry R.H., O'Brien J.T. Elevation in late-life depression of intracellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. The American Journal of Psychiatry 2000, 157(10):1682-1684.
67. Thomas A.J., Davis S., Morris C., Jackson E., Harrison R., O'Brien J.T. Increase in interleukin-1beta in late-life depression. The American Journal of Psychiatry 2005, 162(1):175-177.
68. Tracy R.P., Lemaitre R.N., Psaty B.M., Ives D.G., Evans R.W., Cushman M., Meilahn E.N., Kuller L.H. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arteriosclerosis, Thrombosis, and Vascular Biology 1997, 17(6):1121-1127.
69. Tsuno N., Besset A., Ritchie K. Sleep and depression. Journal of Clinical Psychiatry 2005, 66:1254-1269.
70. Udina M., Moreno-España J., Capuron L., Navinés R., Farré M., Vieta E., Martín-Santos R. Cytokine-induced depression: current status and novel targets for depression therapy. CNS & Neurological Disorders-Drug Targets 2014, 13(6):1066-1074.
71. Uher R., Tansey K.E., Dew T., Maier W., Mors O., Hauser J., Dernovsek M.Z., Henigsberg N., Souery D., Farmer A., McGuffin P. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. American Journal of Psychiatry 2014, 171:1278-1286.
72. Vogelzangs N., Duivis H.E., Beekman A.T., Kluft C., Neuteboom J., Hoogendijk W., Smit J.H., de Jonge P., Penninx B.W. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Translational Psychiatry 2012, 2:e79.
73. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death & Differentiation 2003, 10(1):45-65.
74. Weinberger J.F., Raison C.L., Rye D.B., Montague A.R., Woolwine B.J., Felger J.C., Haroon E., Miller A.H. Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. Brain, Behavior, and Immunity 2014, 47:193-200.
75. Wium-Andersen M.K., Ørsted D.D., Nielsen S.F., Nordestgaard B.G. Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatry 2013, 70(2):176-184.
76. Mental Health Atlas 2011 2011, 82. World Health Organization, World Health Organization (WHO), Geneva.
77. World Health Organization, October 2012. Depression Fact Sheet. Available from (last accessed 20 October 2014). http://www.who.int/mediacentre/factsheets/fs369/en/.
78. Yoshimura R., Hori H., Ikenouchi-Sugita A., Umene-Nakano W., Ueda N., Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2009, 33(4):722-726.
79. Young E.A., Altemus M., Lopez J.F., Kocsis J.H., Schatzberg A.F., DeBattista C., Zubieta J.K. HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology 2004, 29(9):1198-1204.